Vitreo-retinal disease imaging with 3D annular-array ultrasound

项目摘要/摘要 此翻译项目的目标是将定量超声(QUS)功能添加到临床眼科 超声系统，以表征玻璃体不均匀(即，临床上fi不能玻璃体fl复查) 视功能减退)，因为它与健康和疾病的状态有关。年龄相关变化 由于胶原蛋白的交联性和液化聚集性，会产生不均匀的现象 遍及整个玻璃体。对于近视患者来说，这些过程发生在生命的早期，那时玻璃体视网膜 粘附性仍然很强，在与视网膜的粘附性减弱之前，会破坏玻璃体的稳定，导致 影响视力的各种情况。描述玻璃体-视网膜组织的能力将提供独特的早期 视网膜脱离高危近视患者玻璃体视网膜病变的分期检测和评估 以及由牵引引起的玻璃体黄斑病变.. 目前，还没有可用的诊断方法来做出与中发生的更改相关的基于数据的决策 致盲病变之前的玻璃体已经形成。近视即将流行，这造成了一种 临床迫切需要提供客观、灵敏的大分子早期检测手段的技术 玻璃体的变化和结构前体与玻璃体视网膜疾病直接相关。一份诊断报告 能够定量描述整个玻璃体的工具将有助于开发出侵入性更小的和 负担得起的早期干预治疗，如药物玻璃体溶解或激光治疗，以及识别 需要更积极干预的患者行玻璃体切除术。 在与Quantel Medical的合作中，我们将把新的3D探测器和QUS功能整合到 ART，基于20 MHz环形阵列的临床眼科超声系统。该项目的早期阶段将 强调设备增强，以获得必要的原始超声数据，然后是年龄正常和近视 患者数据收集和QUS算法的开发，以在2D中表征玻璃体。后者 该项目的各个阶段将侧重于开发和集成能够进行体积采集的探头， 进一步的患者数据收集，以及利用新的体积数据的QUS Classifi阳离子方法。 fiNAL系统将允许对玻璃体进行定量表征，并允许基于数据的治疗 玻璃体视网膜疾病的决定。虽然这项调查将集中在近视上，但由此产生的技术和 该方法将具有在许多不同的临床环境中应用的潜力。

Project Summary/Abstract The goal of this translational project is to add quantitative ultrasound (QUS) capabilities to a clinical ophthalmic ultrasound system in order to characterize vitreous inhomogeneity (i.e., clinically significant vitreous floaters re- ferred to as Vision Degrading Myodesopsia) as it relates to states of health and disease. Age-related changes due to collagen cross-linking and aggregation with liquefaction create inhomogeneities that appear non-uniformly throughout the vitreous body. For patients with myopia these processes occur earlier in life, when vitreo-retinal adhesion is still strong, and destabilize the vitreous body before adhesion to the retina is weakened, resulting in a variety of conditions that impact vision. The ability to depict vitreo-retinal organization will offer unique early stage detection and assessment of vitreo-retinal disease in patients with myopia at risk for retinal detachment and vitreo-maculopathies resulting from traction.. Currently, no diagnostic method is available to make data-based decisions related to the changes taking place in the vitreous body before blinding pathologies have developed. The impending epidemic of myopia has created an urgent clinical need for technologies offering objective and sensitive means for early detection of macromolecular changes and structural precursors in the vitreous body directly related to vitreo-retinal diseases. A diagnostic tool capable of quantitatively characterizing the entire vitreous body would assist in developing less invasive and affordable treatments for early intervention, such as pharmacologic vitreolysis or laser therapy, and for identifying patients in need of more aggressive interventions with vitrectomy. In collaboration with Quantel Medical, we will incorporate a new 3D probe and QUS capabilities into a state-of- the art, 20-MHz annular-array-based clinical ophthalmic ultrasound system. The early stages of the project will emphasize device enhancements to obtain necessary raw ultrasound data followed by age-normal and myopic patient data collection and development of QUS algorithms to characterize the vitreous body in 2D. The later stages of the project will focus on development and integration of a probe capable of volumetric acquisition, further patient data collection, and QUS classification methods that take advantage of the new volumetric data. The final system will permit quantitative characterization of the vitreous body and allow for data-based treatment decisions of vitreo-retinal diseases. While this investigation will focus on myopia, the resultant technology and approach will have the potential for application in many different clinical settings.